Regulatory Approval Rate KPI

Regulatory Approval Rate is a critical performance indicator that reflects an organization's ability to navigate complex regulatory landscapes efficiently.

High approval rates can lead to faster product launches, improved market access, and enhanced financial health.

Conversely, low rates may indicate potential compliance issues or inefficiencies in the approval process, which can delay revenue generation.

Organizations that prioritize this KPI often see better alignment with strategic goals and improved operational efficiency.

Tracking this metric enables data-driven decision-making and enhances forecasting accuracy, ultimately influencing ROI and overall business outcomes.

How Regulatory Approval Rate Connects to Your Strategy

Regulatory Approval Rate ranks tenth in KPI Depot's Mergers and Acquisitions (M&A) KPI group, which holds forty-five metrics and is led by Cost of M&A Activities, Deal Closure Rate, and Deal Success Rate. Its balanced scorecard perspective is internal process. The rank understates its structural position, because this is a gate metric. Nothing further down the group's priority order happens on a deal that fails to clear it, so Integration Success Rate, Post-Merger Synergies Realized, and Value Created from M&A all describe a population this metric has already filtered.

Its nearest relative in the group is Time to Close, ranked eighth. Regulatory review is often the longest single dependency inside a deal timeline and one of the few a deal team cannot compress by working harder, so the two move together for reasons unrelated to the team's own efficiency. The group flags a rising Deal Closure Rate paired with a rising Time to Close as a bottleneck signal, and on cross-border deals that bottleneck is frequently sitting in a regulator's queue rather than in negotiation.

The tension worth stating plainly runs to M&A Deals Completed and Deal Closure Rate. Approval rate is the metric in this group most easily improved by doing less. An acquirer that walks away from every transaction carrying meaningful antitrust or foreign ownership exposure will post an excellent approval rate against a thin completed-deal count, and on the numbers alone that reads as disciplined execution. Read the three together. Approval rate climbing while M&A Deals Completed falls is a change in risk appetite rather than an improvement in regulatory work, and Value Created from M&A is where the cost of that narrowing eventually shows up.

Measuring Regulatory Approval Rate in Practice

The stored formula is transactions approved over transactions submitted, expressed as a percentage. Both halves need definition before anything is computed, and the definitions are where this metric is won or lost.

A submission is not self-evident. One transaction can require filings in several jurisdictions, so decide whether the unit is the transaction or the filing. Counting filings makes a multi-jurisdiction deal weigh more heavily than a domestic one and turns the metric partly into a measure of deal geography. Counting transactions requires a rule for the deal that clears in most places and fails in one, which is a partial outcome the ratio has no natural slot for.

Approval needs the same discipline. Unconditional clearance, clearance with structural remedies, clearance with behavioral conditions attached, and clearance obtained only after refiling are materially different outcomes. Count all of them and you are measuring whether deals eventually got through. Count only unconditional first-pass clearances and you are measuring the quality of the filings. Both are legitimate. The group's own OKR language points at the second, because it frames the target on initial submissions, and that qualifier is doing real work.

The denominator timing problem is structural and it catches almost everyone. Submissions made in a period and decisions issued in a period are different populations, since review runs for months and often longer. A ratio dividing this period's approvals by this period's submissions mixes them and is biased by construction: submissions still pending have no outcome yet, so they sit in the denominator with no chance of reaching the numerator. The rate reads low while the pipeline grows and high while it shrinks, regardless of how well the regulatory work is being done. The two honest constructions are a cohort rate, which follows the submissions of one period until every one has an outcome, and a decision-period rate, which counts only decisions issued in the period and states which submission periods they came from. Pick one, name it on the report, and keep the same-period ratio out entirely.

Withdrawal before decision is the easiest way to make this metric look good without changing anything. A deal heading for a block is very often pulled first, by agreement or by commercial judgment, and the withdrawn filing leaves the denominator with no rejection recorded anywhere. An approval rate computed over decided matters excludes precisely the population most likely to have failed. Track withdrawals as their own outcome category and read the approval rate next to the withdrawal count, or the metric will improve every time the team gets better at retreating.

Resubmission raises the same accounting question from the other side. When a filing is pulled and refiled, or a remedy package is renegotiated and submitted again, the second filing can be counted as a new submission or as a continuation of the first. Counting it as new inflates the denominator and depresses the rate. Counting it as a continuation hides the rework completely. Neither choice is wrong, but it has to be stated and held, because switching it midway through a series produces a trend that is pure accounting.

Review-cycle lag makes recent periods unreliable in a predictable direction. Simple, uncontested filings clear fastest, so the outcomes visible for a recent submission cohort are disproportionately the easy approvals while the hard matters are still open. A recent period reads strong and then drifts as it matures, which is easy to mistake for declining performance when it is only the cohort filling in. Either restate periods as they close or label the immature ones as provisional.

Mix effects work quietly. A portfolio weighted toward permissive regulators reads better than one weighted toward aggressive ones with no difference in the quality of the work, and jurisdictional mix moves as acquisition strategy moves. Application class does the same: filings in concentrated sectors, filings touching critical infrastructure, and filings involving foreign acquirers face different scrutiny, so changing what you submit changes the rate. Segment by jurisdiction and by matter type before comparing any two periods, and check whether a movement in the headline survives inside the segments.

The interpretive trap is that a high rate is not unambiguously good. An organization submitting only the transactions it is confident about posts a high rate and a thin pipeline, while one pursuing harder transactions posts a lower rate and may create more value doing it. A rate rising while deal volume falls is a signal about appetite, not about compliance capability, and it should be read as a strategic choice rather than a win.

Decisions are also not always final. Appeals, judicial review, and post-decision reversals can change the outcome of a matter after its period has closed and been reported. Decide whether a restated outcome reopens the historical figure or lands in the period the reversal occurs, and hold to it. The underlying records are usually split across the matter management system, outside counsel files, and the filing calendar, and the join between them is exactly where withdrawals and refilings get lost. Reconcile the three before trusting any series built on them.

Common Pitfalls

Many organizations underestimate the complexities of regulatory approvals, leading to avoidable delays and increased costs.

• Failing to engage with regulatory bodies early can result in misalignment. Early communication helps clarify expectations and reduces the likelihood of rejections or delays.
• Inadequate documentation often leads to approval setbacks. Missing or poorly organized documents can frustrate regulators and prolong review times.
• Neglecting to train staff on regulatory requirements creates compliance gaps. Employees unfamiliar with current regulations may overlook critical steps in the approval process.
• Overlooking stakeholder input can hinder the approval process. Engaging all relevant parties ensures a comprehensive understanding of requirements and fosters collaboration.

Improvement Levers

Enhancing the Regulatory Approval Rate requires a proactive approach to compliance and process optimization.

• Develop a centralized repository for regulatory documents to streamline access. This ensures that all team members can quickly locate necessary information, reducing delays in submissions.
• Implement regular training sessions for staff on evolving regulatory standards. Keeping teams informed fosters a culture of compliance and minimizes errors in submissions.
• Establish a cross-functional team to oversee regulatory submissions. Collaboration among departments enhances communication and ensures all perspectives are considered during the approval process.
• Utilize analytics to identify bottlenecks in the approval workflow. Data-driven insights can pinpoint areas for improvement, enabling organizations to optimize their processes effectively.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

Regulatory Approval Rate Benchmarks

We have 4 relevant benchmarks in our benchmarks database.

Browse the Top Benchmarked KPIs in Mergers and Acquisitions (M&A)

Reading the Benchmarks for Regulatory Approval Rate

The tracked sources here measure adjacent things, and none of them measures the ratio this page defines. KPI Depot's set covers merger control enforcement in the United Kingdom from A&O Shearman, United States premerger filing outcomes from Georgetown Law, European Union foreign investment screening from Simpson Thacher & Bartlett, and a cross-jurisdiction study of complex deals from Weil, Gotshal & Manges. Four regimes, four populations, four different questions.

Start with the regime, because merger control and investment screening are not the same gate. Antitrust review asks whether a transaction harms competition. Foreign investment screening asks whether foreign ownership of a particular asset is acceptable, and it catches deals antitrust would never look at. The Simpson Thacher & Bartlett material sits in the second category across European Union member states, while A&O Shearman and Georgetown Law sit in the first. A transaction can clear one gate and fail the other, so an approval rate that pools them describes a composite gate no individual deal actually passes through.

Direction is the next divergence. A&O Shearman reports intervention, the inverse of clean clearance, rather than approval. Converting it into an approval rate means assuming everything not intervened in was approved, which quietly absorbs withdrawals, abandonments, and matters resolved before any formal decision. It also counts cases handled by an authority rather than transactions submitted by a company, and those are different units whenever one transaction produces several filings or one filing covers several transactions.

The denominator is where the set diverges most. Georgetown Law works from a cohort defined by having received a Second Request, the small minority of filings the agencies chose to examine closely. Weil, Gotshal & Manges selects on comparable grounds, complex global deals that drew in-depth review in at least one major jurisdiction. Both are outcome studies of scrutinized deals. The large majority of notified transactions never reach that stage and clear without incident, so a rate computed over the scrutinized cohort and a rate computed over all submissions are not two estimates of one quantity. They answer different questions, and the scrutinized-cohort figure will always read worse.

The form of the reported number differs too. Some are expressed as a share of a cohort, and one is expressed as a band rather than a point, which is itself a signal that the underlying data did not support a single figure. Periods vary from a single recent year to a two-decade run of filings. That is not cosmetic in a metric this sensitive to enforcement posture, which shifts with political appointments and agency priorities. A rate drawn from a permissive stretch and one drawn from an aggressive stretch can describe similar deals under very different regulators.

Underneath all of it sits the question none of the sources fully settles: what counts as an approval. Unconditional clearance, clearance conditioned on remedies or divestitures, clearance restricted in scope, and clearance granted only after refiling are recorded as approvals in some accounting and not in others. A deal that clears after surrendering the asset that motivated it is still an approval on paper. Before any external figure enters a board pack, pin down the regime, the unit, the cohort, and the treatment of conditional clearances. Without those, the number is a label rather than a measurement.

OKRs That Use Regulatory Approval Rate

The M&A KPI group uses Regulatory Approval Rate directly as a key result under its objective to accelerate deal execution without sacrificing thoroughness and compliance, alongside Time to Close, Due Diligence Efficiency, and Contract Review Efficiency. The qualifier the group attaches is the important part: the target is set on initial submissions rather than on eventual approvals. That phrase closes the loophole that otherwise makes this key result easy to hit, since a deal clearing only after being pulled, renegotiated, and refiled has still been approved in the end. Measured on initial submissions, the key result tests filing quality and pre-submission analysis, which is what the objective is actually about.

The group's cross-border objective gives the metric a second and more natural home. Under strengthening legal and regulatory risk management in cross-border transactions, Regulatory Approval Rate is the outcome that Cross-Border Transaction Compliance, Antitrust and Competition Law Compliance, and Legal Risk Exposure Assessment all work toward. Those three measure how well the filing is prepared. This one records whether the regulator agreed. Laddered that way it reads as lagging confirmation rather than something a team can move directly in-quarter, which is the honest role for it.

One guardrail belongs on any target set here. Because the rate improves whenever the organization submits fewer difficult deals, a key result on approval rate should never travel alone. Pair it with M&A Deals Completed or Deal Closure Rate so the objective cannot be satisfied by narrowing the pipeline. Any specific target is a commitment shaped by that team's jurisdictional mix and its own counting rules for conditional clearances, not a level imported from outside.

See OKR Examples for Mergers and Acquisitions (M&A)

Free Whitepaper

Want to achieve performance excellence in Mergers and Acquisitions (M&A)? Download our in-depth whitepaper: Definitive Guide to Mergers and Acquisitions (M&A) KPIs.

Download the Free Guide

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: